Clinical recommendations on diagnosis and treatment of immune checkpoint inhibitor‐induced renal immune‐related adverse events

Immune checkpoint inhibitors (ICIs) are nowadays widely used in clinical oncology treatment, and significantly improve the prognosis of cancer patients. However, overactivation of T cells and related signaling pathways caused by ICIs can also induce immune‐related adverse effects (irAEs). Renal immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Ke, Qiu, Wei, Wang, Hanping, Si, Xiaoyan, Zhang, Xiaotong, Zhang, Li, Li, Xuemei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Clinical Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262914/
https://www.ncbi.nlm.nih.gov/pubmed/32232975
http://dx.doi.org/10.1111/1759-7714.13405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7262914/
https://www.ncbi.nlm.nih.gov/pubmed/32232975
http://dx.doi.org/10.1111/1759-7714.13405

Ejemplares similares